Protein therapeutics biotech using 'protein barcodes' in drug development secures new financing

Two years after kicking things off with $5.4 million, a George Church spinout is refilling its coffers to fuel its efforts tackling protein therapeutics R&D.

Boston biotech Manifold Bio announced the new Series A Thursday, led by new VC Triatomic Capital, raising $40 million to advance its internal pipeline and expand its platform capabilities. CEO and co-founder Gleb Kuznetsov tells Endpoints News that the financing should last the biotech close to 2.5 years, depending on how fast the company spends it.